KR100673266B1 - A growth-promoting composition - Google Patents
A growth-promoting composition Download PDFInfo
- Publication number
- KR100673266B1 KR100673266B1 KR1020060035973A KR20060035973A KR100673266B1 KR 100673266 B1 KR100673266 B1 KR 100673266B1 KR 1020060035973 A KR1020060035973 A KR 1020060035973A KR 20060035973 A KR20060035973 A KR 20060035973A KR 100673266 B1 KR100673266 B1 KR 100673266B1
- Authority
- KR
- South Korea
- Prior art keywords
- extract powder
- weight
- powder
- growth
- extract
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 64
- 239000000843 powder Substances 0.000 claims abstract description 236
- 239000000284 extract Substances 0.000 claims abstract description 157
- 230000012010 growth Effects 0.000 claims abstract description 102
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims abstract description 40
- 239000011575 calcium Substances 0.000 claims abstract description 40
- 229910052791 calcium Inorganic materials 0.000 claims abstract description 40
- 230000001737 promoting effect Effects 0.000 claims abstract description 39
- 241000195649 Chlorella <Chlorellales> Species 0.000 claims abstract description 37
- 240000001008 Dimocarpus longan Species 0.000 claims abstract description 12
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000003937 drug carrier Substances 0.000 claims abstract description 6
- 210000003022 colostrum Anatomy 0.000 claims description 34
- 235000021277 colostrum Nutrition 0.000 claims description 34
- 210000004207 dermis Anatomy 0.000 claims description 15
- 235000013527 bean curd Nutrition 0.000 claims description 14
- 239000007952 growth promoter Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- 235000000235 Euphoria longan Nutrition 0.000 claims description 11
- 241001474374 Blennius Species 0.000 claims description 10
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 claims description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims description 9
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 claims description 9
- 240000002045 Guettarda speciosa Species 0.000 claims description 9
- 235000001287 Guettarda speciosa Nutrition 0.000 claims description 9
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims description 9
- 229940010454 licorice Drugs 0.000 claims description 9
- 235000005078 Chaenomeles speciosa Nutrition 0.000 claims description 8
- 235000017831 Pseudocydonia sinensis Nutrition 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 8
- 235000013372 meat Nutrition 0.000 claims description 8
- 241000283074 Equus asinus Species 0.000 claims description 7
- 235000006679 Mentha X verticillata Nutrition 0.000 claims description 7
- 235000002899 Mentha suaveolens Nutrition 0.000 claims description 7
- 235000001636 Mentha x rotundifolia Nutrition 0.000 claims description 7
- 241000207199 Citrus Species 0.000 claims description 6
- 235000020971 citrus fruits Nutrition 0.000 claims description 6
- 235000020737 peppermint extract Nutrition 0.000 claims description 6
- 229940069774 quince extract Drugs 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 235000017788 Cydonia oblonga Nutrition 0.000 claims description 5
- 239000002775 capsule Substances 0.000 claims description 5
- 239000001848 glycyrrhiza glabra l. root extract powder Substances 0.000 claims description 5
- 239000007901 soft capsule Substances 0.000 claims description 5
- 244000126002 Ziziphus vulgaris Species 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 239000000243 solution Substances 0.000 claims description 2
- 244000251905 Pseudocydonia sinensis Species 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 abstract description 11
- 239000004615 ingredient Substances 0.000 abstract description 4
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 241000255789 Bombyx mori Species 0.000 abstract 1
- 240000006432 Carica papaya Species 0.000 abstract 1
- 235000009467 Carica papaya Nutrition 0.000 abstract 1
- 235000000525 Dimocarpus longan Nutrition 0.000 abstract 1
- 240000008917 Glycyrrhiza uralensis Species 0.000 abstract 1
- 235000000554 Glycyrrhiza uralensis Nutrition 0.000 abstract 1
- 244000245214 Mentha canadensis Species 0.000 abstract 1
- 235000016278 Mentha canadensis Nutrition 0.000 abstract 1
- 241001192908 Phlomis umbrosa Species 0.000 abstract 1
- 244000274050 Platycodon grandiflorum Species 0.000 abstract 1
- 235000006753 Platycodon grandiflorum Nutrition 0.000 abstract 1
- 239000009262 Puerariae Radix plant extract Substances 0.000 abstract 1
- 244000088415 Raphanus sativus Species 0.000 abstract 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 abstract 1
- 241001618264 Rubus coreanus Species 0.000 abstract 1
- 229940002508 ginger extract Drugs 0.000 abstract 1
- 235000020708 ginger extract Nutrition 0.000 abstract 1
- 244000237330 gutta percha tree Species 0.000 abstract 1
- 241000699670 Mus sp. Species 0.000 description 15
- 241000411851 herbal medicine Species 0.000 description 12
- 230000037396 body weight Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 210000000689 upper leg Anatomy 0.000 description 10
- 235000013305 food Nutrition 0.000 description 9
- HMUNWXXNJPVALC-UHFFFAOYSA-N 1-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C(CN1CC2=C(CC1)NN=N2)=O HMUNWXXNJPVALC-UHFFFAOYSA-N 0.000 description 8
- 240000008866 Ziziphus nummularia Species 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 240000000425 Chaenomeles speciosa Species 0.000 description 7
- 235000015872 dietary supplement Nutrition 0.000 description 7
- 238000002156 mixing Methods 0.000 description 7
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 6
- 244000020518 Carthamus tinctorius Species 0.000 description 6
- 240000004670 Glycyrrhiza echinata Species 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 239000011812 mixed powder Substances 0.000 description 6
- 235000016709 nutrition Nutrition 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 5
- 235000008422 Schisandra chinensis Nutrition 0.000 description 5
- 240000006079 Schisandra chinensis Species 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 235000019786 weight gain Nutrition 0.000 description 5
- 230000004584 weight gain Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000013642 negative control Substances 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 235000007516 Chrysanthemum Nutrition 0.000 description 3
- 241000209020 Cornus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 235000006694 eating habits Nutrition 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 210000000963 osteoblast Anatomy 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 235000021067 refined food Nutrition 0.000 description 3
- 239000004576 sand Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 102000008143 Bone Morphogenetic Protein 2 Human genes 0.000 description 2
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 2
- 241001227713 Chiron Species 0.000 description 2
- 240000005250 Chrysanthemum indicum Species 0.000 description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 2
- 240000008067 Cucumis sativus Species 0.000 description 2
- 235000010799 Cucumis sativus var sativus Nutrition 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 102000001554 Hemoglobins Human genes 0.000 description 2
- 108010054147 Hemoglobins Proteins 0.000 description 2
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 2
- 241000234479 Narcissus Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 240000004371 Panax ginseng Species 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- 235000003434 Sesamum indicum Nutrition 0.000 description 2
- 244000040738 Sesamum orientale Species 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 210000003056 antler Anatomy 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000017803 cinnamon Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 229910052571 earthenware Inorganic materials 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- CBOQJANXLMLOSS-UHFFFAOYSA-N ethyl vanillin Chemical compound CCOC1=CC(C=O)=CC=C1O CBOQJANXLMLOSS-UHFFFAOYSA-N 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 208000037824 growth disorder Diseases 0.000 description 2
- 238000005534 hematocrit Methods 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 2
- 235000010234 sodium benzoate Nutrition 0.000 description 2
- 239000004299 sodium benzoate Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- OHVLMTFVQDZYHP-UHFFFAOYSA-N 1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-2-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound N1N=NC=2CN(CCC=21)C(CN1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)=O OHVLMTFVQDZYHP-UHFFFAOYSA-N 0.000 description 1
- LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
- WZFUQSJFWNHZHM-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 WZFUQSJFWNHZHM-UHFFFAOYSA-N 0.000 description 1
- IHCCLXNEEPMSIO-UHFFFAOYSA-N 2-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethanone Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)CC(=O)N1CC2=C(CC1)NN=N2 IHCCLXNEEPMSIO-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241001061264 Astragalus Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 241000282994 Cervidae Species 0.000 description 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 description 1
- 241001148495 Cibotium barometz Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 240000005717 Dioscorea alata Species 0.000 description 1
- 235000002723 Dioscorea alata Nutrition 0.000 description 1
- 235000002727 Dioscorea praehensilis Nutrition 0.000 description 1
- 235000002726 Dioscorea rotundata Nutrition 0.000 description 1
- 239000004278 EU approved seasoning Substances 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AQLLBJAXUCIJSR-UHFFFAOYSA-N OC(=O)C[Na] Chemical compound OC(=O)C[Na] AQLLBJAXUCIJSR-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 235000002634 Solanum Nutrition 0.000 description 1
- 241000207763 Solanum Species 0.000 description 1
- 240000006394 Sorghum bicolor Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229910000004 White lead Inorganic materials 0.000 description 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 description 1
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 1
- 231100000403 acute toxicity Toxicity 0.000 description 1
- 230000007059 acute toxicity Effects 0.000 description 1
- 238000011047 acute toxicity test Methods 0.000 description 1
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 1
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000006533 astragalus Nutrition 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000021061 dietary behavior Nutrition 0.000 description 1
- 238000007598 dipping method Methods 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 229940073505 ethyl vanillin Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 235000013402 health food Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 238000007602 hot air drying Methods 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011785 micronutrient Substances 0.000 description 1
- 235000013369 micronutrients Nutrition 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000019629 palatability Nutrition 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 description 1
- 230000009645 skeletal growth Effects 0.000 description 1
- 229940023144 sodium glycolate Drugs 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 210000004233 talus Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- JEJAMASKDTUEBZ-UHFFFAOYSA-N tris(1,1,3-tribromo-2,2-dimethylpropyl) phosphate Chemical compound BrCC(C)(C)C(Br)(Br)OP(=O)(OC(Br)(Br)C(C)(C)CBr)OC(Br)(Br)C(C)(C)CBr JEJAMASKDTUEBZ-UHFFFAOYSA-N 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/05—Chlorophycota or chlorophyta (green algae), e.g. Chlorella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 성장촉진제에 관한 것이다. 좀 더 구체적으로, 본 발명은 해조칼슘, 식물추출물, 클로렐라추출물, 맥아추출물 및 초유분말로 구성된 조성물을 유효성분으로 하고, 약제학적으로 허용되는 담체를 포함하는 성장촉진제에 관한 것이다.The present invention relates to a growth accelerator. More specifically, the present invention relates to a growth accelerator comprising a composition consisting of seaweed calcium, plant extract, chlorella extract, malt extract and colostrum powder as an active ingredient and a pharmaceutically acceptable carrier.
현대의 눈부신 과학의 발달과 의학의 발달에 의하여, 평균수명이 현저하게 증가되었음에도 불구하고, 현대인들은 건강한 삶을 영위하지 못하고 있는데, 이는 산업사회에서의 과다한 경쟁에서 오는 여러가지 스트레스, 심각한 환경오염, 불균형적인 식습관 등에 기인하는 것으로 여겨지고 있다. 이중에서도, 불균형적인 식습관은 건강한 삶을 유지할 수 없게 하는데, 가장 직접적으로 영향을 미치는 요인이다. In spite of the remarkable increase in life expectancy and the development of medicine, modern people are not living a healthy life because of the stress, serious environmental pollution and imbalances that arise from excessive competition in industrial society. It is believed to be due to ordinary eating habits. Among them, unbalanced eating habits make it impossible to maintain a healthy life, which is the most direct factor.
급격한 기술의 발달에 의하여 식량의 생산량이 증대되면서, 절대빈곤이 해결된 후에는, 허기를 해결하는 식품의 일차적인 기능이외에, 좀 더 맛있는 식품, 오 래두고 먹을 수 있는 식품 등을 간편하게 먹을 수 있는 방법에 대하여 관심을 기울이고 연구를 하게 되었고, 그 결과 식품 첨가물의 개발과 더불어 인스턴트 식품, 정제가공식품이 발달하게 되었다. 이처럼 개발된 각종 가공식품은, 시각과 미각적인 기호성을 충족시키고, 저장성이 향상되었으나, 이에 상응하는 다양한 부작용이 나타나고 있는 실정이다. 즉, 가공식품의 제조과정중에 미량 영양소가 소실되어, 영양의 불균형이 초래되고, 화학조미료, 발색제, 방부제 등의 과다사용에 의하여 체내의 항상성을 왜곡시킴으로써, 유아 또는 성장기의 어린아이의 성장을 저해하고, 성인병의 조기발생을 촉진시키는 부작용이 나타나고 있다.As the production of food increases due to the rapid development of technology, after absolute poverty is resolved, in addition to the primary function of foods that solve hunger, it is easier to eat more delicious foods and foods that can be eaten for a long time. Attention has been paid to researching methods, and as a result, the development of food additives and the development of instant foods and processed foods. Various processed foods developed as described above satisfy the visual and taste palatability and have improved shelf life, but various side effects appear. That is, micronutrients are lost during the manufacturing process of processed foods, resulting in nutritional imbalances, and distorting the homeostasis of the body due to overuse of chemical seasonings, colorants, and preservatives, thereby inhibiting the growth of infants and young children. And, side effects that promote the early development of adult diseases are appearing.
성장을 의학적으로 정의하면, 성숙에 수반되는 크기의 변화라고 할 수 있으며, 특히 소아의 성장이라 함은 신장의 증가 뿐만 아니라 신체의 각 기관의 크기와 기능의 증대를 포괄적으로 포함하는 개념이지만, 일반적으로는 신장의 증가에 국한되어 사용된다. 이같은 신장의 증가는 연골조직의 합성, 골격길이 성장 및 골격조직의 광범위한 증식을 포함하는 골격대사를 통하여 이루어지는데, 이러한 신장 증가는 소아의 건강상태, 영양, 호르몬, 유전적 배경을 나타내는 예민한 지표로서 활용되고 있다.When medically defined, growth is a change in size accompanying maturity. In particular, growth in children is a concept that encompasses not only an increase in height but also an increase in the size and function of each organ of the body, It is used only for the increase in height. This increase in kidney is achieved through skeletal metabolism, which includes the synthesis of cartilage tissue, skeletal length growth, and extensive growth of skeletal tissue, which is a sensitive indicator of the health, nutrition, hormones, and genetic background of children. It is utilized.
일반적으로, 사람의 성장을 살펴볼 때, 대개 유전적인 영향이 가장 크게 영향을 미치는 것으로 여겨지고 있으나, 실제로는 유전적인 영향은 23% 정도 밖에 해당되지 않으며, 나머지 77%는 후천적 영향에 의해 결정되는데, 구체적으로는 영양 31%, 운동 20%, 환경이 16%, 기타 10% 정도라는 연구결과가 보고되었다(참조, 가와하다 아이요시, '키가 크는 비결', 제일미디어, 개정판 1쇄 1997. 6. 9 인쇄, 1997. 6. 13 발행). 따라서, 성장을 촉진시키기 위해서는, 인스턴트 식품의 섭취를 줄이고 영양의 균형화, 적절한 운동, 오염 환경의 개선 등이 요구되지만, 이중에서도 영향의 균형화가 가장 중요한 요인으로 지적되고 있다.In general, when looking at human growth, genetic influences are generally considered to have the greatest impact, but in reality, genetic influence is only about 23%, and the remaining 77% is determined by acquired influences. The results of this study were reported to be 31% nutrition, 20% exercise, 16% environment, and other 10% (cf. Kawada Aiyoshi, `` The Secret to Tall '', Cheil Media, Rev. 1, 1997). 9 printed, issued June 13, 1997). Therefore, in order to promote growth, it is necessary to reduce the intake of instant foods, to balance nutrition, to exercise appropriately, to improve the pollution environment, etc. Among these, the balance of influence is pointed out as the most important factor.
이처럼 영양의 균형화를 달성하여 궁극적으로는 성장을 촉진시키기 위하여는, 현재까지는 식생활 행태를 전적으로 변화시켜야 하지만, 이는 현실적으로 불가능하기 때문에, 이의 대안으로서, 성장촉진을 위한 건강보조식품을 섭취하는 방법이 제기되었고, 이에 따라, 영양의 균형을 보조하여 성장을 촉진할 수 있는 다양한 건강보조식품이 개발되고 있는 실정이다. In order to achieve this nutritional balance and ultimately promote growth, it is necessary to completely change the dietary behavior so far, but this is not practical, so as an alternative, there is a way to take dietary supplements to promote growth. Accordingly, various health supplements that can promote growth by supporting nutrition balance are being developed.
예를 들어, 대한민국 특허등록 제 278206호에는 홍화씨, 두충, 백복령, 복분자, 토사자, 및 녹각과 칼슘을 함유하는 성장촉진용 건강보조식품 조성물이 개시되어 있고, 대한민국 특허등록 제 404455호에는 가시오가피(Acanthopanax senticosus), 숙지황, 산약, 산수유, 복령, 녹각 및 인삼의 한약재로부터 추출된 추출물을 유효성분으로 하는 성장 장애 치료 및 예방용 약학적 제제가 개시되어 있으며, 대한민국 특허공개 제 2003-306호에는 산조인 분말 또는 추출물을 포함하는 성장촉진용 식품이 개시되어 있고, 대한민국 특허공개 제 2003-12714호에는 녹용, 숙지황, 황기, 당귀, 구기자, 백작약, 백출, 오가피, 홍삼, 영지, 오미자, 홍화씨의 혼합 추출물을 젤리형태로 성형한 성장촉진용 건강식품 및 그의 제조방법이 개시되어 있으며, 대한민국 특허공개 제 2003-86158호에는 홍화씨, 녹각, 석창포, 토사자, 복분자, 국화, 백복령, 산조인, 결명자, 구기자, 마(산약), 황기, 계피, 건강 및 감초의 혼합추출물을 포함하는 건강보조식품 조성물이 개시되어 있고, 대한 민국 특허공개 제 2004-11748호에는 골 대사과정에서 BMP-2(Bone morphogenetic protein-2)의 발현을 증가시키는 방각궐과의 금모구척(Cibotium barometz L. J. SMITH)의 조추출물 또는 가용추출물을 유효성분으로 하는 성장 장애 증후군의 예방 및 치료용 약학적 조성물 및 전기 추출물을 포함하는 건강보조식품이 개시되어 있으며, 대한민국 특허공개 제 2004-92861호에는 홍화씨, 토사자, 복분자, 백복령, 당귀, 산수유, 목단피, 창출, 천궁, 녹용, 및 택사의 혼합추출물을 포함하는 성장촉진용 건강보조식품 조성물이 개시되어 있다. For example, Korean Patent Registration No. 278206 discloses a growth promoting health supplement composition containing safflower seed, tofu, baekbokyeong, bokbunja, earth and sand, and greenery and calcium, and Korean Patent Registration No. 404455 discloses Agathopanax. senticosus), Sukjihwang, mountain Chinese medicine, cornus milk, Bokryeong, green tea and ginseng extracts are disclosed as a pharmaceutical agent for the treatment and prevention of growth disorders as an active ingredient, Korean Patent Publication No. 2003-306 Or a growth-promoting food comprising an extract is disclosed, Korean Patent Publication No. 2003-12714 discloses a mixed extract of antler, Sukjiwang, Astragalus, Angelica, Gugija, Baekjak, Baekchul, Ogapi, red ginseng, ganoderma lucidum, Schisandra chinensis, safflower seed A growth promoting health food molded in a jelly form and a method of manufacturing the same are disclosed, and Korean Patent Publication No. 2003-86158 A health supplement composition comprising a mixed extract of safflower seed, green stone, Seokchangpo, earth and sand, bokbunja, chrysanthemum, baekbokyeong, sanjoin, gyeoljak, wolfberry, hemp, yellow, cinnamon, health and licorice is disclosed, Korean patent Publication No. 2004-11748 discloses a growth disorder using crude or soluble extract of Cibotium barometz LJ SMITH, which increases the expression of BMP-2 (Bone morphogenetic protein-2) in bone metabolism. Health supplements comprising pharmaceutical compositions for the prevention and treatment of syndromes and electric extracts are disclosed. Korean Patent Laid-Open No. 2004-92861 discloses safflower seed, earth and sand, bokbunja, baekbokyeong, Angelica, cornus, velvet skin, creation, cheongung, A growth promoting health supplement composition comprising a mixed extract of deer antler, and taxa is disclosed.
그러나, 이러한 종래의 건강보조식품 또는 성장촉진용 의약품은 골격의 성장만을 지나치게 중요시한 나머지, 일시적으로나마 복용자의 체내 대사를 비정상적으로 활성화시킬 수도 있다는 문제점이 제기되어, 실질적으로는 활용되지 못하고 있는 실정이다.However, such conventional dietary supplements or growth promoting drugs are so important that only the growth of the skeleton is too important, and may temporarily activate abnormally the metabolism of the body of the user, which is not practically utilized. .
따라서, 성장을 촉진시킬 수 있으면서도, 복용자의 체내 대사에 영향을 미치지 않는 새로운 성장촉진제를 개발하여야 할 필요성이 끊임없이 대두되었다.Thus, there is a constant need to develop new growth promoters that can promote growth but do not affect the body's metabolism.
이에, 본 발명자들은 성장을 촉진시킬 수 있으면서도, 복용자의 체내 대사에 영향을 미치지 않는 새로운 성장촉진제를 개발하고자 예의 연구노력한 결과, 해조칼슘, 식물추출물, 클로렐라추출물, 맥아추출물 및 초유분말로 구성된 조성물을 유효성분으로 하고 약재학적으로 허용되는 담체를 포함하는 성장촉진제를 이용할 경 우, 복용자의 체내 대사에 영향을 미치지 않으면서도, 골격의 성장을 촉진시킬 수 있음을 확인하고, 본 발명을 완성하게 되었다. Accordingly, the present inventors have made intensive studies to develop new growth accelerators that can promote growth but do not affect the body's metabolism. As a result, the composition comprising seaweed calcium, plant extracts, chlorella extracts, malt extracts and colostrum powder When using a growth accelerator comprising the carrier as an active ingredient and a pharmaceutically acceptable carrier, it was confirmed that the growth of the skeleton can be promoted without affecting the metabolism of the body of the recipient, the present invention was completed.
결국, 본 발명의 주된 목적은 성장촉진효과를 나타내는 조성물을 제공하는 것이다.After all, the main object of the present invention is to provide a composition that exhibits a growth promoting effect.
본 발명의 다른 목적은 전기 조성물을 유효성분으로 하는 성장촉진제를 제공하는 것이다.Another object of the present invention is to provide a growth accelerator comprising the electrical composition as an active ingredient.
본 발명의 성장촉진제는 칼슘분말 25 내지 35중량%, 클로렐라추출물분말 5 내지 10중량%, 초유분말 5 내지 10중량%, 산약추출물분말 1 내지 10중량%, 오가피추출물분말 1 내지 10중량%, 맥아추출물분말 1 내지 5중량%, 진피추출물분말 1 내지 5중량%, 나복자추출물분말 0.5 내지 5중량%, 탱자추출물분말 0.5 내지 5중량%, 오미자추출물분말 0.5 내지 5중량%, 복분자추출물분말 0.5 내지 5중량%, 용안육추출물분말 0.5 내지 5중량%, 당귀추출물분말 0.5 내지 5중량%, 두충추출물분말 0.5 내지 3.0중량%, 모과추출물분말 0.5 내지 3.0중량%, 속단추출물분말 0.5 내지 3.0중량%, 백강잠추출물분말 0.5 내지 3.0중량%, 갈근추출물분말 0.5 내지 3.0중량%, 길경추출물분말 0.5 내지 3.0중량%, 대추추출물분말 0.5 내지 3.0중량%, 감초추출물분말 0.1 내지 1.0중량%, 박하추출물분말 0.1 내지 1.0중량% 및 건강추출물분말 0.1 내지 0.5중량%로 구성된 성장촉진용 조성물을 유효성분으로 하고, 약제학적으 로 허용된 담체를 포함한다: 이때, 칼슘분말은 특별히 이에 제한되지 않으나, 해조로부터 추출한 해조칼슘분말을 사용함이 바람직하고, 클로렐라추출물분말은 특별히 이에 제한되지 않으나, 클로렐라를 동결건조시켜 수득한 건조분말을 사용함이 바람직하며, 초유분말은 특별히 이에 제한되지 않으나, 소의 초유를 열풍건조하여 수득함이 바람직하다. 아울러, 산약, 오가피, 맥아, 진피, 나복자, 탱자, 오미자, 복분자, 용안육, 당귀, 두충, 모과, 속단, 백강잠, 갈근, 길경, 대추, 감초, 박하 및 건강의 추출물분말은 특별히 이에 제한되지 않으나, 이들 한약재를 열수추출하여 수득함이 바람직하다. Growth promoter of the present invention, 25 to 35% by weight of calcium powder, 5 to 10% by weight of chlorella extract powder, 5 to 10% by weight of colostrum powder, 1 to 10% by weight of powdered powder of extract powder, 1 to 10% by weight of organic extract powder, malt Extract powder 1 to 5% by weight, dermis extract powder 1 to 5% by weight, moth extract powder 0.5 to 5% by weight, tanza extract powder 0.5 to 5% by weight, Schizandra extract powder 0.5 to 5% by weight, bokbunja extract powder 0.5 to 5 Weight%, Longan meat extract powder 0.5 to 5% by weight, Angelica extract powder 0.5 to 5% by weight, Tofu extract powder 0.5 to 3.0% by weight, Chinese quince extract powder 0.5 to 3.0% by weight, Fast extract powder 0.5 to 3.0% by weight, Baekgang submersible extract 0.5 to 3.0% by weight of powder, brown extract powder 0.5 to 3.0% by weight, 0.5 to 3.0% by weight of citrus extract powder, 0.5 to 3.0% by weight of jujube extract powder, 0.1 to 1.0% by weight licorice extract powder, 0.1 to 1.0% by weight peppermint extract powder % And A growth promoting composition composed of 0.1 to 0.5% by weight of health extract powder is an active ingredient, and includes a pharmaceutically acceptable carrier. The calcium powder is not particularly limited thereto, but seaweed calcium powder extracted from seaweed is used. It is preferable that the chlorella extract powder is not particularly limited, but it is preferable to use a dry powder obtained by lyophilizing chlorella, and the colostrum powder is not particularly limited thereto, but is preferably obtained by hot air drying bovine colostrum. In addition, acid powder, cucumber, malt, dermis, nabokjakja, tanza, schizandra, bokbunja, longan meat, donkey, tofu, quince, sesame, baekjap, brown root, gilyeong, jujube, licorice, mint and health extract powder is not particularly limited It is preferable to obtain these herbal medicines by hot water extraction.
먼저, 본 발명자들은 골격의 성장은 골격을 형성하는 조골세포에 칼슘이 흡수되는 일련의 대사과정에 의하여 수행됨에 착안하여, 칼슘이 조골세포에 흡수되는 과정을 효과적으로 보조할 수 있는 성분을 개발하기 위하여, 다양한 성분을 대상으로 하여 검색한 결과, 칼슘분말을 클로렐라추출물 및 초유분말과 혼합하여 동물에 경구투여할 경우, 칼슘이 조골세포에 흡수되어 골격이 성장할 수 있음을 확인하였다. 그러나, 이들을 경구투여한 경우에는 골격의 성장은 수행되었으나, 체중이 오히려 감소하는 현상이 관찰되었다. 본 발명자들은 이러한 문제점을 해결하고자, 성장촉진 효과를 보조할 수 있는 보조성분을 검색한 결과, 산약, 오가피, 맥아, 진피, 나복자, 탱자, 오미자, 복분자, 용안육, 당귀, 두충, 모과, 속단, 백강잠, 갈근, 길경, 대추, 감초, 박하 및 건강의 혼합추출물을 사용할 경우, 이러한 문제점을 해결할 수 있음을 확인하였다. First, the present inventors pay attention to the growth of the skeleton is carried out by a series of metabolic processes in which calcium is absorbed by osteoblasts forming the skeleton, in order to develop a component that can effectively assist the process of calcium is absorbed by osteoblasts As a result of searching for various components, it was confirmed that when calcium powder was orally administered to animals mixed with chlorella extract and colostrum powder, calcium could be absorbed by osteoblasts and bones could grow. However, when they were orally administered, the growth of the skeleton was performed, but the phenomenon of weight loss was observed. In order to solve this problem, the present inventors search for supplementary ingredients that can assist the growth promoting effect, as a result, powder, ogapi, malt, dermis, nabokjak, Tenja, Schisandra chinensis, Bokbunja, Longan meat, Angelica, tofu, Chinese quince, Sokcho, It was confirmed that this problem can be solved by using a mixed extract of Baekjap, brown root, Gilkyung, jujube, licorice, mint and health.
이때, 각 성분은 칼슘분말 25 내지 35중량%, 클로렐라추출물분말 5 내지 10중량%, 초유분말 5 내지 10중량%, 산약추출물분말 1 내지 10중량%, 오가피추출물분말 1 내지 10중량%, 맥아추출물분말 1 내지 5중량%, 진피추출물분말 1 내지 5중량%, 나복자추출물분말 0.5 내지 5중량%, 탱자추출물분말 0.5 내지 5중량%, 오미자추출물분말 0.5 내지 5중량%, 복분자추출물분말 0.5 내지 5중량%, 용안육추출물분말 0.5 내지 5중량%, 당귀추출물분말 0.5 내지 5중량%, 두충추출물분말 0.5 내지 3.0중량%, 모과추출물분말 0.5 내지 3.0중량%, 속단추출물분말 0.5 내지 3.0중량%, 백강잠추출물분말 0.5 내지 3.0중량%, 갈근추출물분말 0.5 내지 3.0중량%, 길경추출물분말 0.5 내지 3.0중량%, 대추추출물분말 0.5 내지 3.0중량%, 감초추출물분말 0.1 내지 1.0중량%, 박하추출물분말 0.1 내지 1.0중량%, 건강추출물분말 0.1 내지 0.5중량%의 조성비로 포함하는 것이 바람직하다. 전기 각 성분 중에서, 칼슘분말, 클로렐라추출물 및 초유분말을 이들의 함량범위보다 적은 양으로 포함할 경우에는 성장촉진효과가 현저히 감소되었고, 이들의 함량범위보다 많은 양으로 포함할 경우에는 더이상 성장촉진효과가 증가되지 않음을 알 수 있었다. 또한, 전기 각 성분 중에서, 산약, 오가피, 맥아, 진피, 나복자, 탱자, 오미자, 복분자, 용안육, 당귀, 두충, 모과, 속단, 백강잠, 갈근, 길경, 대추, 감초, 박하 및 건강을 이들의 함량범위를 벗어날 경우에는 골격의 성장율에 비하여 체중의 증가율이 미치지 못함을 알 수 있었다.At this time, each component is 25 to 35% by weight calcium powder, 5 to 10% by weight chlorella extract powder, 5 to 10% by weight colostrum powder, 1 to 10% by weight powder extract powder, 1 to 10% by weight of Ogapi extract powder, malt extract 1 to 5% by weight of powder, 1 to 5% by weight of dermis extract powder, 0.5 to 5% by weight of narcissus extract powder, 0.5 to 5% by weight of tanza extract powder, 0.5 to 5% by weight of Schizandra chinensis extract powder, 0.5 to 5% by weight of bokbunja extract powder %, Longan meat extract powder 0.5 to 5% by weight, Angelica extract powder 0.5 to 5% by weight, tofu extract powder 0.5 to 3.0% by weight, quince extract powder 0.5 to 3.0% by weight, fast extract powder 0.5 to 3.0% by weight, Baekkang submerged extract powder 0.5 to 3.0% by weight, brown extract powder 0.5 to 3.0% by weight, 0.5 to 3.0% by weight citrus extract powder, 0.5 to 3.0% by weight extract powder, licorice extract powder 0.1 to 1.0% by weight, peppermint extract powder 0.1 to 1.0% by weight , Health extraction To include in the composition ratio of the powder of 0.1 to 0.5% by weight. Among each of the above components, the growth promoting effect was significantly reduced when calcium powder, chlorella extract and colostrum powder were contained in less than their content range. It was found that was not increased. In addition, among the above components, acid, cucumber, malt, dermis, nabokjak, tanza, schizandrae, bokbunja, longan, donkey, tofu, quince, soybean paste, white sperm, brown root, gilyeong, jujube, licorice, mint and health In case of out of range, the increase rate of body weight was less than that of skeletal growth rate.
이에, 본 발명자들은 칼슘분말 25 내지 35중량%, 클로렐라추출물분말 5 내지 10중량%, 초유분말 5 내지 10중량%, 산약추출물분말 1 내지 10중량%, 오가피추출물분말 1 내지 10중량%, 맥아추출물분말 1 내지 5중량%, 진피추출물분말 1 내지 5중량%, 나복자추출물분말 0.5 내지 5중량%, 탱자추출물분말 0.5 내지 5중량%, 오미자추출물분말 0.5 내지 5중량%, 복분자추출물분말 0.5 내지 5중량%, 용안육추출물분말 0.5 내지 5중량%, 당귀추출물분말 0.5 내지 5중량%, 두충추출물분말 0.5 내지 3.0중량%, 모과추출물분말 0.5 내지 3.0중량%, 속단추출물분말 0.5 내지 3.0중량%, 백강잠추출물분말 0.5 내지 3.0중량%, 갈근추출물분말 0.5 내지 3.0중량%, 길경추출물분말 0.5 내지 3.0중량%, 대추추출물분말 0.5 내지 3.0중량%, 감초추출물분말 0.1 내지 1.0중량%, 박하추출물분말 0.1 내지 1.0중량%, 건강추출물분말 0.1 내지 0.5중량%를 포함하는 조성물을 "성장촉진용 조성물"이라 명명하였다.Thus, the present inventors 25 to 35% by weight calcium powder, 5 to 10% by weight chlorella extract powder, 5 to 10% by weight colostrum powder, 1 to 10% by weight powder extract powder, 1 to 10% by weight of ogapi extract powder, malt extract 1 to 5% by weight of powder, 1 to 5% by weight of dermis extract powder, 0.5 to 5% by weight of narcissus extract powder, 0.5 to 5% by weight of tanza extract powder, 0.5 to 5% by weight of Schizandra chinensis extract powder, 0.5 to 5% by weight of bokbunja extract powder %, Longan meat extract powder 0.5 to 5% by weight, Angelica extract powder 0.5 to 5% by weight, tofu extract powder 0.5 to 3.0% by weight, quince extract powder 0.5 to 3.0% by weight, fast extract powder 0.5 to 3.0% by weight, Baekkang submerged extract powder 0.5 to 3.0% by weight, brown extract powder 0.5 to 3.0% by weight, 0.5 to 3.0% by weight citrus extract powder, 0.5 to 3.0% by weight extract powder, licorice extract powder 0.1 to 1.0% by weight, peppermint extract powder 0.1 to 1.0% by weight , health A composition comprising a powder chulmul 0.1 to 0.5% by weight was named "for growth-promoting composition".
한편, 본 발명의 성장촉진제의 유효성분으로 함유되는 성장촉진용 조성물은 약학적으로 허용가능한 결합제(예, 폴리비닐피롤리돈, 하이드록시프로필셀룰로오스), 붕해제(예, 카복시메틸셀룰로오스칼슘, 전분글리콜산나트륨), 희석제(예, 옥수수전분, 유당, 콩기름, 결정셀룰로오스, 만니톨), 활택제(예, 스테아린산 마그네슘, 탈크), 감미제(예, 백당, 과당, 솔비톨, 아스파탐), 안정제(카복시메틸셀룰로오스나트륨, 알파 또는 베타 싸이클로덱스트린, 비타민 C, 구연산, 백납), 보존료(예, 파라옥시안식향산메틸, 파라옥시안식향산프로필, 안식향산나트륨) 및 향료(예, 에틸바닐린, 마스킹후레바, 멘톨후라보노, 허브향)와 혼합하여 정제, 캅셀제, 연질캅셀제, 액제, 연고제 또는 주사제와 같은 약학적 제제로 제조될 수 있다. On the other hand, the growth promoting composition contained as an active ingredient of the growth promoter of the present invention is a pharmaceutically acceptable binder (e.g. polyvinylpyrrolidone, hydroxypropyl cellulose), disintegrant (e.g. carboxymethyl cellulose calcium, starch) Sodium glycolate), diluents (e.g. corn starch, lactose, soybean oil, crystalline cellulose, mannitol), lubricants (e.g. magnesium stearate, talc), sweeteners (e.g. white sugar, fructose, sorbitol, aspartame), stabilizers (carboxymethyl Sodium cellulose, alpha or beta cyclodextrin, vitamin C, citric acid, white lead), preservatives (e.g. methyl paraoxybenzoate, propyl paraoxybenzoate, sodium benzoate) and flavorings (e.g. ethyl vanillin, masking flavor, menthol flavono, Herb flavor) can be prepared into pharmaceutical preparations such as tablets, capsules, soft capsules, solutions, ointments or injections.
성장촉진용 조성물의 Of growth promoting composition 급성독성실험Acute Toxicity Test
6 내지 7주령 된 비설치류 비글견(beagle)을 대상으로 본 발명의 성장촉진용 조성물을 경구투여하여 24시간내의 개체사망율을 조사하였으며, 이때 암컷은 6 내지 8㎏인 개체를, 수컷은 7 내지 9㎏인 개체를 각각 8마리 사용하였다. 그 결과, 5g/kg 까지 죽은 개체가 발생하지 않아, 본 발명의 성장촉진용 조성물은 kg당 5g까지도 급성독성을 관찰할 수 없을 만큼 안전하므로, 성장촉진제로서 생체내에 안전하게 투여할 수 있다. The mortality rate was examined within 24 hours by orally administering the growth promoting composition of the present invention to non-rodent beagle dogs 6 to 7 weeks old, wherein the females were 6 to 8 kg and the males were 7 to 7 kg. Eight individuals weighing 9 kg were used. As a result, the dead individuals do not occur up to 5g / kg, the growth promoting composition of the present invention is safe enough to observe acute toxicity even up to 5g per kg, it can be safely administered in vivo as a growth promoter.
유효량Effective amount
본 발명에 있어서 성장촉진용 조성물의 투여량은 환자의 연령, 성별, 증상, 투여방법 또는 예방목적에 따라, 체중 kg 당 6 내지 30㎎을 일일 1회 내지 3회 분복할 수 있다. 특이 증상을 나타내는 환자에 대한 투여용량 수준은 환자의 체중, 연령, 성별, 건강상태, 식이, 투여시간, 투여방법, 배설율, 질환의 중증도 등에 따라 당업자가 투여량을 변화시킬 수도 있다. In the present invention, the dosage of the growth promoting composition may be divided into 6 to 30 mg / kg body weight once or three times per day, depending on the age, sex, symptoms, administration method or preventive purpose of the patient. Dosage levels for patients with specific symptoms may vary by those skilled in the art depending on the patient's weight, age, sex, health condition, diet, time of administration, method of administration, rate of excretion, severity of disease, and the like.
본 발명의 성장촉진제는 복용자의 체내 대사에 영향을 미치지 않으면서도, 효과적으로 골격의 성장을 촉진하므로, 유아 및 어린이의 성장촉진에 널리 활용될 수 있을 것이다.The growth promoter of the present invention may be widely used for promoting growth of infants and children, because it effectively promotes bone growth without affecting the body's metabolism.
이하, 실시예를 통하여 본 발명을 보다 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention in more detail, it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited by these examples in accordance with the gist of the present invention. .
실시예 1: 성장촉진효과를 나타내는 조성물의 제조 Example 1 : Preparation of a composition showing a growth promoting effect
실시예 1-1: 칼슘, 클로렐라추출물 및 초유분말을 포함하는 조성물의 수득 Example 1-1 Obtaining a Composition Comprising Calcium, Chlorella Extract and Colostrum Powder
해조칼슘분말(National Food, 뉴질랜드), 클로렐라추출물분말(National Food, 뉴질랜드) 및 초유분말(남양유업, 한국)을 하기의 각 조성비로 포함하는 각각의 조성물을 수득하였다(참조: 표 1a).Seaweed calcium powder (National Food, New Zealand), Chlorella extract powder (National Food, New Zealand) and colostrum powder (Namyang Dairy, Korea) were obtained for each composition comprising the following composition ratios (see Table 1a).
실시예 1-2: 칼슘, 클로렐라추출물 및 초유분말을 포함하는 조성물의 성장촉진효과 Example 1-2 growth promoting effect of a composition comprising calcium, chlorella extract and colostrum powder
먼저, 생후 3주령의 웅성 마우스 10마리의 체장, 체중, 대퇴골의 길이 및 대퇴골의 무게를 측정하여 평균값을 수득하고 이를 기준값으로 사용하였다. 이때, 체장은 마우스를 마취시키고, 코끝부터 꼬리끝 부분까지의 길이를 사용하였고, 이들 마우스로 부터 각각의 대퇴골을 적출한 다음, 적출된 대퇴골의 길이 및 무게를 측정하였다.First, the body length, body weight, the length of the femur and the weight of the femur of 10 male mice at 3 weeks of age were measured to obtain an average value, which was used as a reference value. At this time, the body was anesthetized with the mouse, the length from the tip of the nose to the tip of the tail, each of the femur was removed from these mice, and then the length and weight of the extracted femur was measured.
이어, 전기 실시예 1-1에서 수득한 각 조성물을 10%(w/w)로 혼합한 사료를 각각 생후 3주령의 웅성 마우스 10마리에 3주간 섭식시키고, 이들의 체장, 체중, 대퇴골의 길이 및 대퇴골의 무게를 측정하여 각각의 평균값을 수득하여 이를 실험값으로 사용하였다. 그런 다음, 전기 기준값과 실험값을 하기의 계산식에 적용하여 각각의 성장율을 산출하고, 각 실험군의 마우스별로 비교하였다. 이때, 대조군으로는 전기 조성물을 섭식시키지 않은 마우스를 사용하였다.(참조: 표 1b).Subsequently, the feed obtained by mixing each composition obtained in Example 1-1 at 10% (w / w) was fed to 10 male 3-week-old male mice for 3 weeks, and their length, weight, and femur length And the weight of the femur was measured to obtain the average value of each was used as an experimental value. Then, the growth rate was calculated by applying the electrical reference value and the experimental value to the following formula, and compared with each mouse in each experimental group. At this time, the control group was used mice that did not feed the electrical composition (see Table 1b).
성장율(%) = ( 실험값 - 기준값 )/기준값 x 100% Growth = (experimental value-reference value) / reference value x 100
상기 표 1b에서 보듯이, 칼슐분말에 클로렐라추출물분말 및 초유분말이 각각 혼합된 것보다, 두가지 성분이 모두 혼합된 경우에, 골격의 성장이 촉진되었고, 칼슘분말, 클로렐라추출물분말 및 초유분말의 혼합비가 5:1:1 및 7:2:2(w/w/w)인 경우에, 골격의 성장율이 현저하게 증가됨을 알 수 있었다.As shown in Table 1b, the growth of the skeleton was promoted when both components were mixed with the chlorella extract powder and the colostrum powder, and the calcium powder, the chlorella extract powder, and the colostrum powder were mixed. Is 5: 1: 1 and 7: 2: 2 (w / w / w), it can be seen that the growth rate of the skeleton is significantly increased.
그러나, 체중의 성장율에서 보듯이, 칼슘분말, 클로렐라추출물분말 및 초유분말의 혼합비가 5:1:1 및 7:2:2(w/w/w)인 경우에는 대조군 보다도 체중성장율이 감소됨을 확인하였다However, as shown in the growth rate of the body weight, when the mixing ratio of calcium powder, chlorella extract powder and colostrum powder is 5: 1: 1 and 7: 2: 2 (w / w / w), it was confirmed that the weight growth rate was reduced compared to the control group. Was
실시예 2: 칼슘, 클로렐라추출물 및 초유분말을 포함하는 조성물의 보조성분 결정 Example 2 Determination of Supplementary Components of a Composition Containing Calcium, Chlorella Extract and Colostrum Powder
전기 실시예 1-2의 결과에서 보듯이, 칼슘, 클로렐라추출물 및 초유분말을 포함하는 조성물의 단점을 극복하여, 체중의 성장율까지도 향상시킬 수 있는 보조성분을 검색하고, 이의 적정 함량을 결정하고자 하였다.As shown in the results of the above Example 1-2, to overcome the disadvantages of the composition containing calcium, chlorella extract and colostrum powder, to search for an auxiliary component that can improve the growth rate of the body weight, and to determine the appropriate content thereof .
실시예 2-1: 보조성분 검색 Example 2-1 : Supplementary Ingredient Search
칼슘분말, 클로렐라추출물분말 및 초유분말이 7:2:2(w/w/w)로 혼합된 혼합분말 60g과 성장촉진효과가 있다고 알려진 다양한 한약재의 열수추출분말 40g을 혼합하고, 이를 사료 900g과 혼합하여 각각의 실험사료 1000g을 수득하였다. 이때, 한약재로는 속단, 홍화씨, 탱자, 두충, 백복령, 복분자, 모과, 토사자, 녹각, 오가피, 숙지황, 산약, 산수유, 복령, 백강잠, 인삼, 길경, 산조인, 대추, 황기, 당귀, 구기자, 진피, 백작약, 맥아, 백출, 영지, 오미자, 석창포, 나복자, 국화, 갈근, 결명자, 계피, 건강, 감초, 목단피, 창출, 천궁, 용안육, 택사 및 박하를 사용하였다. 아울러, 이들의 열수추출분말은 상기 각 한약재 1kg을 10L의 물에 침지하고, 100℃로 5시간동안 가열한 다음, 이를 여과하여 액상성분만을 수득하고, 전기 액상성분을 열풍분무건조하여 수득하였다.Mix 60g of mixed powder of calcium powder, chlorella extract powder and colostrum powder at 7: 2: 2 (w / w / w) with 40g of hot water extract powder of various herbal medicines known to have growth promoting effects. Mixing yielded 1000 g of each experimental feed. At this time, as Chinese herbal medicine, Sokdan, safflower seed, tanza, tofu, baekbokyeong, bokbunja, quince, earthenware, greenery, ogapi, sagejiku, mountain medicine, cornus, bokyeong, baekgangjam, ginseng, gilyeong, sanjoin, jujube, yellow rice, donkey, gugija, dermis , Count, Malt, Baekchul, Ganoderma, Schisandra chinensis, Seokchangpo, Naboja, Chrysanthemum, Root, Cassia, Cinnamon, Health, Licorice, Bark Peel, Creation, Cheongung, Dragon Meat, Talc and Mint. In addition, these hot water extraction powder was obtained by dipping 1 kg of each medicinal herb in 10 L of water, heating at 100 ° C. for 5 hours, and filtering it to obtain only a liquid component, and drying the electric liquid component by hot air spray drying.
이어, 전기 수득한 각 실험사료를 생후 3주령의 웅성 마우스 10마리에 3주간 섭식시키는 것을 제외하고는, 전기 실시예 1-2의 방법으로 체중의 성장율을 산출하고, 각 실험군의 마우스별로 비교하였다. 이때, 양성대조군으로는 칼슘분말, 클로렐라추출물분말 및 초유분말이 7:2:2(w/w/w)로 혼합된 혼합분말만을 섭식시킨 마우스를 사용하고, 음성대조군으로는 전기 혼합분말을 섭식시키지 않은 마우스를 사용하였다.(참조: 표 1c).Subsequently, except for feeding each experimental feed obtained before, to 10 male mice at 3 weeks of age for 3 weeks, the growth rate of the body weight was calculated by the method of Examples 1-2, and compared with each mouse of each experimental group. . At this time, as a positive control group, mice fed only a mixed powder containing calcium powder, chlorella extract powder and colostrum powder at 7: 2: 2 (w / w / w) were used, and as a negative control group, the electric mixed powder was fed. Mice were not used (see Table 1c).
상기 표 1c에서 보듯이, 다양한 한약재 중에서, 산약, 오가피, 맥아, 진피, 나복자, 탱자, 오미자, 복분자, 용안육, 당귀, 두충, 모과, 속단, 백강잠, 갈근, 길경, 대추, 감초, 박하 및 건강을 사용할 경우, 음성대조군의 수준으로 체중증가율이 회복됨을 알 수 있었으므로, 이들을 혼합하여 사용할 경우, 체중증가율을 더욱 향상시킬 수 있는지를 확인하였다.As shown in Table 1c, among various herbal medicines, powder, ogapi, malt, dermis, nabokjak, tanza, schizandra, bokbunja, longan, donkey, tofu, Chinese quince, fast, baekgangjam, brown root, gilyeong, jujube, licorice, mint and health When using, since it was found that the weight gain rate is recovered to the level of the negative control group, it was confirmed that when used in combination, the weight gain rate can be further improved.
이에, 산약, 오가피, 맥아, 진피, 나복자, 탱자, 오미자, 복분자, 용안육, 당귀, 두충, 모과, 속단, 백강잠, 갈근, 길경, 대추, 감초, 박하 및 건강의 혼합추출분말 60g을 수득하고, 칼슘분말, 클로렐라추출물분말 및 초유분말이 7:2:2(w/w/w)로 혼합된 혼합분말 40g과 혼합한 다음, 이를 사료 900g과 혼합하여 실험사료 1000g을 수득하였다. 이어, 전기 수득한 실험사료를 생후 3주령의 웅성 마우스 10마리에 3주간 섭식시키는 것을 제외하고는, 전기 실시예 1-2의 방법으로 체중의 성장율을 산출한 결과, 평균 267%의 체중증가율을 나타냄을 확인하였다.Thus, to obtain 60 g of mixed extract powder of powder, ogapi, malt, dermis, nabokjaja, tanza, schizandra, bokbunja, longan, donkey, tofu, Chinese quince, sesame, baeksjap, brown root, gilyeong, jujube, licorice, mint and health, Calcium powder, chlorella extract powder and colostrum powder were mixed with 40 g of mixed powder mixed at 7: 2: 2 (w / w / w), and then mixed with 900 g of feed to obtain 1000 g of experimental feed. Subsequently, except that the experimental feed obtained before feeding to 10 male mice three weeks of age for three weeks, the growth rate of the body weight was calculated by the method of Examples 1-2, and the average weight gain rate was 267%. It confirmed that it was shown.
따라서, 전기 한약재의 혼합추출분말을 사용할 경우, 칼슘분말, 클로렐라추출물분말 및 초유분말로 구성된 조성물의 단점을 해결할 수 있음을 알 수 있었다.Therefore, it can be seen that the use of the mixed extract powder of the herbal medicine can solve the disadvantages of the composition consisting of calcium powder, chlorella extract powder and colostrum powder.
실시예 2-2: 보조성분의 함량 결정 Example 2-2 : content determination of auxiliary components
전기 실시예 2-1에서 선별된 각 한약재의 적정함량을 결정하고자, 하기와 같이 각 한약재의 혼합비를 달리하여 수득한 추출분말을 칼슘분말, 클로렐라추출물분말 및 초유분말과 혼합한 혼합물 100g을 수득하고, 이를 사료 900g과 혼합하여 각각의 실험사료 1000g을 수득하였다(참조: 표 1d).In order to determine the appropriate content of each herbal medicine selected in the previous Example 2-1, 100 g of a mixture of calcium powder, chlorella extract powder and colostrum powder obtained by extracting powder obtained by varying the mixing ratio of each herbal medicine was obtained as follows. This was mixed with 900 g of feed to obtain 1000 g of each experimental feed (see Table 1d).
이어, 전기 수득한 각 실험사료를 생후 3주령의 웅성 마우스 10마리에 3주간 섭식시키는 것을 제외하고는, 전기 실시예 1-2의 방법으로 체중의 성장율을 산출하고, 각 실험군의 마우스별로 비교하였다. 이때, 양성대조군으로는 칼슘분말, 클로렐라추출물분말 및 초유분말이 7:2:2(w/w/w)로 혼합된 혼합분말만을 섭식시킨 마우스를 사용하고, 음성대조군으로는 전기 혼합분말을 섭식시키지 않은 마우스를 사용하였다.(참조: 표 1e). 이때, 대조군으로는 칼슘분말, 클로렐라추출물분말 및 초유분말이 7:2:2(w/w/w)로 혼합된 혼합물 100g을 사료 900g과 혼합한 실험사료 1000g을 섭식시킨 마우스를 사용하였다.Subsequently, except for feeding each experimental feed obtained before, to 10 male mice at 3 weeks of age for 3 weeks, the growth rate of the body weight was calculated by the method of Examples 1-2, and compared with each mouse of each experimental group. . At this time, as a positive control group, mice fed only a mixed powder containing calcium powder, chlorella extract powder and colostrum powder at 7: 2: 2 (w / w / w) were used, and as a negative control group, the electric mixed powder was fed. Mice were not used. (Table 1e). At this time, as a control, mice fed with 1000 g of experimental feed mixed with 900 g of feed and 100 g of a mixture of calcium powder, chlorella extract powder and colostrum powder at 7: 2: 2 (w / w / w) were used.
상기 표 1e에서 보듯이, 대조군의 체중성장율과 비교하여 실험군 2 내지 7의 체중성장율은 현저하게 증가되었으나, 실험군 1의 체중성장율은 대조군의 체중성장율과 차이가 없었고, 실험군 8의 체중성장율은 대조군의 체중성장율 보다는 다소 증가하였으나, 실험군 2 내지 7의 체중성장율에는 미치지 못함을 알 수 있었다.As shown in Table 1e, the weight growth rate of the experimental groups 2 to 7 was significantly increased compared to the weight growth rate of the control group, the weight growth rate of the experimental group 1 was not different from the weight growth rate of the control group, the weight growth rate of the experimental group 8 of the control group Although slightly increased than the weight growth rate, it was found that the weight growth rate of the experimental groups 2 to 7 did not reach.
상기 표 1d 및 1e의 결과를 종합하면, 본 발명의 성장촉진효과를 나타내는 조성물은 칼슘분말 25 내지 35중량%, 클로렐라추출물분말 5 내지 10중량%, 초유분말 5 내지 10중량%, 산약추출물분말 1 내지 10중량%, 오가피추출물분말 1 내지 10중량%, 맥아추출물분말 1 내지 5중량%, 진피추출물분말 1 내지 5중량%, 나복자추출물분말 0.5 내지 5중량%, 탱자추출물분말 0.5 내지 5중량%, 오미자추출물분말 0.5 내지 5중량%, 복분자추출물분말 0.5 내지 5중량%, 용안육추출물분말 0.5 내지 5중량%, 당귀추출물분말 0.5 내지 5중량%, 두충추출물분말 0.5 내지 3.0중량%, 모과추출물분말 0.5 내지 3.0중량%, 속단추출물분말 0.5 내지 3.0중량%, 백강잠추출물분말 0.5 내지 3.0중량%, 갈근추출물분말 0.5 내지 3.0중량%, 길경추출물분말 0.5 내지 3.0중량%, 대추추출물분말 0.5 내지 3.0중량%, 감초추출물분말 0.1 내지 1.0중량%, 박하추출물분말 0.1 내지 1.0중량% 및 건강추출물분말 0.1 내지 0.5중량%를 포함하는 것이 바람직함을 알 수 있었다.Putting together the results of Tables 1d and 1e, the composition showing the growth promoting effect of the present invention is 25 to 35% by weight calcium powder, 5 to 10% by weight chlorella extract powder, 5 to 10% by weight colostrum powder, powdered powder powder 1 To 10% by weight, Ogai extract powder 1 to 10% by weight, malt extract powder 1 to 5% by weight, dermis extract powder 1 to 5% by weight, moth extract powder 0.5 to 5% by weight, tanza extract powder 0.5 to 5% by weight, Schisandra chinensis extract powder 0.5 to 5 wt%, bokbunja extract powder 0.5 to 5 wt%, long eye extract powder 0.5 to 5 wt%, Angelica extract powder 0.5 to 5 wt%, Tofu extract powder 0.5 to 3.0 wt%, Chinese quince extract powder 0.5 to 5 wt% 3.0% by weight, fast extract powder 0.5-3.0% by weight, white-nap extract powder 0.5-3.0% by weight, brown root extract powder 0.5-3.0% by weight, citrus extract powder 0.5-3.0% by weight, date extract 0.5-3.0% by weight, licorice extract It was found to be preferable to include the end of 0.1 to 1.0% by weight of peppermint extract powder, 0.1 to 1.0% by weight and health extract powder, 0.1 to 0.5% by weight.
이에, 본 발명자들은 전기 조성물을 "성장촉진용 조성물"이라 명명하고, 이하에서는 성장촉진용 조성물의 효과를 알아보았다.Thus, the present inventors named the electrical composition "composition for growth," and looked at the effect of the growth-promoting composition below.
실시예 3: 성장촉진용 조성물의 효과 Example 3 Effect of Growth Promoting Composition
전기 실시예 2의 성장촉진용 조성물을 생쥐에 투여하여, 생쥐의 외형적인 성장과 혈액조성의 변화를 비교함으로써, 성장촉진용 조성물의 효과를 측정하였다.The growth promoting composition of Example 2 was administered to the mice, and the effect of the growth promoting composition was measured by comparing the external growth of the mice with changes in blood composition.
실시예 3-1: 성장촉진용 조성물의 제조 Example 3-1 Preparation of Growth Promoting Composition
칼슘분말 30중량%, 클로렐라추출물분말 8.0중량%, 초유분말 8.0중량%, 산약추출물분말 5.0중량%, 오가피추출물분말 5.0중량%, 맥아추출물분말 3.0중량%, 진피추출물분말 3.0중량%, 나복자추출물분말 2.0중량%, 탱자추출물분말 2.0중량%, 오미자추출물분말 2.0중량%, 복분자추출물분말 3.0중량%, 용안육추출물분말 5.0중량%, 당귀추출물분말 5.0중량%, 두충추출물분말 3.0중량%, 모과추출물분말 3.0중량%, 속단추출물분말 3.0중량%, 백강잠추출물분말 3.0중량%, 갈근추출물분말 2.0중량%, 길경추출물분말 1.0중량%, 대추추출물분말 2.0중량%, 감초추출물분말 1.0중량%, 박하추출물분말 0.5중량% 및 건강추출물분말 0.5중량%을 각각 정량하여 혼합함으로써, 성장촉진용 조성물을 제조하였다.30% by weight calcium powder, 8.0% by weight chlorella extract powder, 8.0% by weight colostrum powder, 5.0% by weight powder from powdered extracts, 5.0% by weight of extract powder, malt extract powder, 3.0% by weight malt extract powder, 3.0% by weight dermis extract powder 2.0 wt%, Tanga extract powder 2.0 wt%, Schisandra chinensis extract powder 2.0 wt%, Bokbun extract powder 3.0 wt%, Longan extract powder 5.0 wt%, Angelica extract powder 5.0 wt%, Tofu extract powder 3.0 wt%, Chinese quince extract powder 3.0 Weight%, fast extract powder 3.0%, white yam extract powder 3.0% by weight, root extract powder 2.0% by weight, citrus extract powder 1.0% by weight, jujube extract powder 2.0% by weight, licorice extract powder 1.0% by weight, peppermint extract powder 0.5% by weight % And 0.5% by weight of the healthy extract powder, respectively, by quantitatively mixing to prepare a composition for growth promotion.
그런 다음, 체장, 꼬리, 등뼈, 대퇴골의 길이, 대퇴골의 무게, 체중 및 사료섭취량이 각각 측정된 3주령의 웅성 마우스를 대상으로 하여, 일반사료를 섭식시킨 10마리의 대조군과 전기 제조된 성장촉진용 조성물과 사료가 1:9(w/w)로 혼합된 혼합사료를 섭식시킨 10마리의 실험군을 각각 3주간 사육하였다.Then, 10 control rats fed the normal diet and the pre-growth growth of 3 male males whose body length, tail, spine, femur length, femur weight, weight and feed intake were measured. Ten experimental groups were fed for three weeks, each fed a mixed feed mixed with a composition for feeding and 1: 9 (w / w).
실시예 3-2: 외형적인 성장에 미치는 성장촉진용 조성물의 효과 Example 3-2 Effect of Growth Promoting Composition on External Growth
전기 실시예 3-1에서 사육한 대조군과 실험군의 체장, 꼬리의 길이, 체중 및 사료섭취량을 사육시작 시점에서 측정된 값으로 환산하여, 이들의 증가율을 산출하고, 산출된 증가율의 평균값을 비교하였다(참조: 표 2a). The body length, tail length, weight, and feed intake of the control group and the experimental group raised in Example 3-1 were converted to the values measured at the start of breeding, and their growth rates were calculated, and the average values of the calculated growth rates were compared. (See Table 2a).
상기 표 2a에서 보듯이, 대조군에 비하여 실험군이 모든 비교항목에서 우수한 효과를 나타냄을 알 수 있었다.As shown in Table 2a, it was found that the experimental group showed excellent effects in all comparison items compared to the control group.
실시예 3-3: 혈액조성에 미치는 성장촉진용 조성물의 효과 Example 3-3 Effect of Growth Promoting Composition on Blood Composition
전기 실시예 3-1에서 사육한 대조군과 실험군으로부터 채혈하고, 채혈된 혈액에 포함된 백혈구의 수, 적혈구의 수, 헤모글로빈의 중량, 헤마토크릿치(hematocrit value) 및 혈소판의 수를 혈액자동분석기(CHIRON EXPRESS PLUS, Chiron Limited, USA)로 측정하고, 이를 비교하였다(참조: 표 2b). Blood samples were collected from the control group and the experimental group bred in Example 3-1, and the number of leukocytes, red blood cells, hemoglobin weight, hematocrit value, and platelet count contained in the collected blood was measured by a blood autoanalyzer (CHIRON). EXPRESS PLUS, Chiron Limited, USA) and compared (Table 2b).
상기 표 2b에서 보듯이, 대조군에 비하여 실험군이 모든 비교항목에서 동등한 수준을 나타내었으며, 이는 성장촉진용 조성물이 투여될 경우, 복용자의 체내 대사에 별다른 영향을 미치지 않음을 의미하는 것으로 분석되었다.As shown in Table 2b, the experimental group showed the same level in all comparison items compared to the control group, which means that when the growth promoting composition is administered, it does not have a significant effect on the body's metabolism.
상기 표 2a 및 2b의 결과를 종합하면, 본 발명의 성장촉진용 조성물은 복용자의 체내 대사에 별다른 영향을 미치지 않으면서도, 외형적인 성장율을 크게 증진시킬 수 있음을 확인할 수 있었다.Combining the results of Tables 2a and 2b, it was confirmed that the growth promoting composition of the present invention can significantly increase the apparent growth rate without significantly affecting the body's metabolism.
실시예 4: 성장촉진제의 제제화 Example 4 Formulation of Growth Promoters
본 발명의 성장촉진용 조성물을 통상의 부형제, 결합제, 윤활제, 붕해제, 희석제 등과 같은 보조제와 혼합하여 다음과 같은 약학적 제제로 제조하였다.The growth promoting composition of the present invention was mixed with auxiliaries such as excipients, binders, lubricants, disintegrants, diluents and the like to prepare a pharmaceutical formulation as follows.
실시예 4-1: 정제의 제조 Example 4-1 Preparation of Tablets
실시예 3-1의 성장촉진용 조성물 10mg, 유당 20mg, 전분 20mg 및 스테아린산 마그네슘 적당량을 통상의 정제 제조방법에 따라서 50mg의 정제로 타정하여, 정제형의 성장촉진제를 제조하였다.10 mg, lactose 20 mg, starch 20 mg, and magnesium stearate in an appropriate amount of the composition for promoting growth of Example 3-1 were compressed into 50 mg tablets according to a conventional tablet preparation method to prepare a growth accelerator in a tablet form.
실시예 4-2: 캅셀제의 제조 Example 4-2 Preparation of Capsule
실시예 3-1의 성장촉진용 조성물 10mg, 유당 20mg, 전분 19mg, 탈크 1mg 및 스테아린산 마그네슘 적당량을 통상 캅셀제의 제조방법에 따라서 50mg 용량의 캅셀에 충진하여, 캅셀제형의 성장촉진제를 제조하였다.10 mg, lactose 20 mg, starch 19 mg, talc 1 mg, and magnesium stearate in an appropriate amount of the growth promoting composition of Example 3-1 were filled in a 50 mg capsule according to a method for preparing a capsule, and a growth accelerator of a capsule formulation was prepared.
실시예 4-3: 액제의 제조 Example 4-3 Preparation of Liquid
실시예 3-1의 성장촉진용 조성물 100mg, 이성화당 10g, 벌꿀 500mg, 니코틴산아마이드(약전) 20mg, 무수카페인(약전) 30mg 및 안식향산나트륨 70mg을 통상의 액제 제조방법에 따라서 제조하고, 100ml 용량의 갈색병에 충진한 다음, 밀전하여 저온 살균처리함으로써, 액제형의 성장촉진제를 제조하였다.100 mg of the growth promoting composition of Example 3-1, 10 g of isomerized sugar, 500 mg of honey, 20 mg of nicotinic acid (pharmaceutical), caffeine anhydrous (30 mg) and 70 mg of sodium benzoate were prepared according to a conventional method for preparing a liquid, After filling into a brown bottle, it was intimately pasteurized to prepare a liquid growth accelerator.
실시예 4-4: 연질캅셀제의 제조 Example 4-4 Preparation of Soft Capsule
젤라틴 52중량%, 글리세린 32중량%, ANIDRISORB 11중량% 및 물 5중량%를 사용하여 작제된 외피용 조성물에, 실시예 3-1의 성장촉진용 조성물 10mg, 폴리에틸렌글리콜 230mg 및 글리세린 13mg을 넣고, 통상의 연질캅셀 제조방법에 따라서, 연질캅셀제형의 성장촉진제를 제조하였다.10 mg of growth-promoting composition of Example 3-1, 230 mg of polyethylene glycol, and 13 mg of glycerin were added to the skin composition prepared using 52% by weight of gelatin, 32% by weight of glycerin, 11% by weight of ANIDRISORB, and 5% by weight of water. According to the conventional soft capsule manufacturing method, the growth accelerator of the soft capsule type | mold was manufactured.
실시예 4-5: 과립제의 제조 Example 4-5 Preparation of Granules
실시예 3-1의 성장촉진용 조성물 10mg 및 유당 25mg을 통상의 압출조립기로 압출시켜서, 과립제형의 성장촉진제를 제조하였다.10 mg of the growth promoting composition of Example 3-1 and 25 mg of lactose were extruded with a conventional extrusion granulator to prepare a growth accelerator in a granular form.
이상에서 상세히 설명하고 입증하였듯이, 본 발명은 해조칼슘, 식물추출물, 클로렐라추출물, 맥아추출물 및 초유분말로 구성된 성장촉진용 조성물을 유효성분으로 하고, 약제학적으로 허용되는 담체를 포함하는 성장촉진제를 제공한다. 본 발명의 성장촉진제는 복용자의 체내 대사에 영향을 미치지 않으면서도, 효과적으로 골격의 성장을 촉진하므로, 유아 및 어린이의 성장촉진에 널리 활용될 수 있을 것이다.As described and demonstrated in detail above, the present invention provides a growth accelerator comprising a growth promoting composition comprising seaweed calcium, plant extract, chlorella extract, malt extract and colostrum powder as an active ingredient, and a pharmaceutically acceptable carrier. do. The growth promoter of the present invention may be widely used for promoting growth of infants and children, because it effectively promotes bone growth without affecting the body's metabolism.
Claims (5)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020060035973A KR100673266B1 (en) | 2006-04-21 | 2006-04-21 | A growth-promoting composition |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020060035973A KR100673266B1 (en) | 2006-04-21 | 2006-04-21 | A growth-promoting composition |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR100673266B1 true KR100673266B1 (en) | 2007-01-24 |
Family
ID=38014605
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020060035973A KR100673266B1 (en) | 2006-04-21 | 2006-04-21 | A growth-promoting composition |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR100673266B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015076631A1 (en) * | 2013-11-25 | 2015-05-28 | 경희대학교 산학협력단 | Composition for preventing or treating growth disorders, containing malt extracts |
| WO2015147559A1 (en) * | 2014-03-28 | 2015-10-01 | (주)솔빛피앤에프 | Composition for promoting growth comprising chaenomeles sinesis as active ingredient |
| KR101615991B1 (en) * | 2014-12-31 | 2016-04-29 | 대상 주식회사 | Composition for promoting growth comprising chlorella extract and herbal extract powder |
| CN109511976A (en) * | 2018-11-09 | 2019-03-26 | 章茨伍 | A kind of Japanese Premna Herb peppermint health preservation powder production method |
-
2006
- 2006-04-21 KR KR1020060035973A patent/KR100673266B1/en active IP Right Grant
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015076631A1 (en) * | 2013-11-25 | 2015-05-28 | 경희대학교 산학협력단 | Composition for preventing or treating growth disorders, containing malt extracts |
| KR20150060572A (en) * | 2013-11-25 | 2015-06-03 | 경희대학교 산학협력단 | Composition for Preventing or Treating Short Stature Comprising Hordeum vulgare Extract |
| KR101659667B1 (en) | 2013-11-25 | 2016-09-23 | 경희대학교 산학협력단 | Composition for Preventing or Treating Short Stature Comprising Hordeum vulgare Extract |
| US11324795B2 (en) | 2013-11-25 | 2022-05-10 | University-Industry Cooperation Group Of Kyung Hee University | Composition comprising Hordeum vulgare extract for preventing or treating short stature |
| WO2015147559A1 (en) * | 2014-03-28 | 2015-10-01 | (주)솔빛피앤에프 | Composition for promoting growth comprising chaenomeles sinesis as active ingredient |
| KR101615991B1 (en) * | 2014-12-31 | 2016-04-29 | 대상 주식회사 | Composition for promoting growth comprising chlorella extract and herbal extract powder |
| CN109511976A (en) * | 2018-11-09 | 2019-03-26 | 章茨伍 | A kind of Japanese Premna Herb peppermint health preservation powder production method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103141709B (en) | Carp feed and preparation method thereof | |
| KR101793531B1 (en) | A composition and functional food comprising an combination extract of Atractylodes macrocephala KOIDZ, Morus alba L., Lycium chinensis, Euphoria lingan STEUD, Achyranthus japonica NAKAI, Eucommia ulmoides OLIV and Asparagus cochinchinensis MERR for preventing or treating postmenopause syndrome | |
| KR102049440B1 (en) | Composition for preventing and improving woman climacterium symptoms comprising extract of Polygonum cuspidatum Sieb. et Zucc. and Cinnamomum cassia Blume | |
| KR100715653B1 (en) | Growth-promoting foodstuff | |
| KR102416513B1 (en) | Composition for preventing and improving pet constipation and manufacturing method thereof | |
| KR100673266B1 (en) | A growth-promoting composition | |
| KR101559130B1 (en) | Composition comprising herbal extract for preventing or treating obesity | |
| EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
| KR100678519B1 (en) | A composition comprising the extract of Semisulospira libertine Sulfur Fed Duck Ulmus devidiana Pine Pollen Powder Acer tegmentosum Maxim. Bamboo Salt Artemisia capillaries Platycodon Grandiflorum Rhynchosiavolubilis for the prevention and treatment of fatty liver | |
| CN105433382B (en) | A kind of maca composition and its preparation method and application | |
| KR101822834B1 (en) | Composition for improving menopausal symptom | |
| CN105535094A (en) | Traditional Chinese medicine composition for facilitating beast, bird and fish production performance | |
| CN102784230B (en) | Pharmaceutical composition preparation for treating nutritional anemia | |
| KR100679290B1 (en) | A composition comprising an extract of ?????201 crude drug complex as an effective ingredient treating or preventing obesity | |
| CN101143203B (en) | Compound oral liquid with liver-protecting and stomach-nourishing function | |
| JP5884112B2 (en) | Muscle enhancer | |
| KR101479096B1 (en) | Health functional food comprising extracts of herbal mixture for preventing or improving edema of delivered or pregnant woman | |
| KR101992174B1 (en) | Tablet-type composition for preventing and relieving hangover, and protecting hepatic caused by alcohol containing medical herbs | |
| KR101896815B1 (en) | Health functional food composition for anorexia improvement and pharmaceutical composition for preventing or treating anorexia improvement | |
| CN109731037A (en) | A kind of pharmaceutical composition and its application promoting gastrointestinal peristalsis | |
| CN103142751A (en) | Traditional Chinese medicine composition for treating piglet iron-deficiency anemia | |
| KR20170143149A (en) | Composition for promoting growth comprising medicinal herb extracts | |
| CN107233490A (en) | A kind of maca composition of supplementing qi and nourishing yin beautifying face and moistering lotion | |
| CN102579713B (en) | Traditional Chinese medicine for treating children obesity and preparation method | |
| JP2002187847A (en) | Composition for supplying calcium |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20121130 Year of fee payment: 7 |
|
| FPAY | Annual fee payment |
Payment date: 20131030 Year of fee payment: 8 |
|
| FPAY | Annual fee payment |
Payment date: 20150417 Year of fee payment: 9 |
|
| FPAY | Annual fee payment |
Payment date: 20160113 Year of fee payment: 10 |
|
| FPAY | Annual fee payment |
Payment date: 20170207 Year of fee payment: 11 |
|
| FPAY | Annual fee payment |
Payment date: 20171124 Year of fee payment: 12 |
|
| FPAY | Annual fee payment |
Payment date: 20181119 Year of fee payment: 13 |
|
| FPAY | Annual fee payment |
Payment date: 20191113 Year of fee payment: 14 |